{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:22:33Z","timestamp":1787494953684,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"US Office of Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-21-1-0065"],"award-info":[{"award-number":["W81XWH-21-1-0065"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-17-RHUS-0003"],"award-info":[{"award-number":["ANR-17-RHUS-0003"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93020C00045"],"award-info":[{"award-number":["75N93020C00045"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["75N930220C00042"],"award-info":[{"award-number":["75N930220C00042"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EU H2020-847939-IP-cure-B"],"award-info":[{"award-number":["EU H2020-847939-IP-cure-B"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtm.2025.101646","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:20:33Z","timestamp":1763648433000},"page":"101646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination"],"prefix":"10.1016","volume":"33","author":[{"given":"Bai-Hua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Horrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Luckenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-1553","authenticated-orcid":false,"given":"Yong-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101646_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101646_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101646_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.omtm.2025.101646_bib6","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/v16121828","article-title":"New Insights on Hepatitis B Virus Viral Transcription in Single Hepatocytes","volume":"16","author":"Peng","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.omtm.2025.101646_bib7","first-page":"335","article-title":"A new antigen complex co-occurring with Australia antigen. Acta pathologica et microbiologica Scandinavica","volume":"80","author":"Magnius","year":"1972","journal-title":"Section B: Microbiol. Immunol."},{"key":"10.1016\/j.omtm.2025.101646_bib8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtm.2025.101646_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","author":"Laras","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101646_bib11","article-title":"Assembly and release of hepatitis B virus","volume":"5","author":"Selzer","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.omtm.2025.101646_bib12","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/jvi.65.3.1310-1317.1991","article-title":"Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus","volume":"65","author":"Summers","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib13","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1128\/jvi.68.9.5706-5713.1994","article-title":"Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes","volume":"68","author":"Lenhoff","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib14","doi-asserted-by":"crossref","first-page":"11916","DOI":"10.1128\/JVI.05373-11","article-title":"Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus","volume":"85","author":"Lentz","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib15","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1128\/JVI.02721-06","article-title":"Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein","volume":"81","author":"Gao","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-virology-092818-015508","article-title":"The hepatitis B virus envelope proteins: molecular gymnastics throughout the viral life cycle","volume":"7","author":"Seitz","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib17","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1073\/pnas.72.11.4597","article-title":"Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles","volume":"72","author":"Summers","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101646_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1128\/jvi.36.3.829-836.1980","article-title":"Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus","volume":"36","author":"Mason","year":"1980","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib19","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.omtm.2025.101646_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.29509","article-title":"A research agenda for curing chronic hepatitis B virus infection","volume":"67","author":"Alter","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2025.101646_bib22","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1073\/pnas.88.10.4186","article-title":"Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis","volume":"88","author":"Brunetto","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101646_bib23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","article-title":"Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection","volume":"2","author":"Carman","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101646_bib24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/apt.15381","article-title":"Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant","volume":"50","author":"Jiang","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.omtm.2025.101646_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1053\/jhep.2000.17912","article-title":"Long-term therapy of chronic hepatitis B with lamivudine","volume":"32","author":"Lau","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib27","doi-asserted-by":"crossref","first-page":"e0129525","DOI":"10.1128\/jvi.01295-25","article-title":"Replication-driven HBV cccDNA loss in chimeric mice with humanized livers","volume":"99","author":"Zhang","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib28","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.omtm.2025.101646_bib29","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/jvi.64.6.2819-2824.1990","article-title":"Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification","volume":"64","author":"Summers","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","article-title":"Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo","volume":"67","author":"Allweiss","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.omtm.2025.101646_bib31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101646_bib32","author":"KoshAgarwal"},{"key":"10.1016\/j.omtm.2025.101646_bib33","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib34","article-title":"The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice","author":"Lempp","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtm.2025.101646_bib35","article-title":"Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA","volume":"2","author":"Lai","year":"2020","journal-title":"JHEP Rep."},{"key":"10.1016\/j.omtm.2025.101646_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101646_bib37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101646_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101646_bib39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101646_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101646_bib41","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1073\/pnas.1407362111","article-title":"Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice","volume":"111","author":"Deal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2025.101646_bib42","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000150411","article-title":"Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene","volume":"38","author":"Magnius","year":"1995","journal-title":"Intervirology"},{"key":"10.1016\/j.omtm.2025.101646_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0161-5890(90)90169-Z","article-title":"Hepatitis B surface antigen particles with all four subtypic determinants: point mutations of hepatitis B virus DNA inducing phenotypic changes or double infection with viruses of different subtypes","volume":"27","author":"Yamanaka","year":"1990","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101646_bib45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/infdis\/131.6.708","article-title":"Subtypes of hepatitis B surface antigen in Southeast Asia","volume":"131","author":"Snitbhan","year":"1975","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtm.2025.101646_bib46","first-page":"727","article-title":"HBs antigen subtypes among acute hepatitis patients in Japan: evidence of imported hepatitis","volume":"83","author":"Shiina","year":"1988","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.omtm.2025.101646_bib47","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1016\/j.vaccine.2020.09.083","article-title":"Epidemiological distribution of hepatitis B virus genotypes in 1\u201329-year-olds in the mainland of China","volume":"38","author":"Su","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2025.101646_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000096313","article-title":"Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea","volume":"50","author":"Kim","year":"2007","journal-title":"Intervirology"},{"key":"10.1016\/j.omtm.2025.101646_bib49","first-page":"1","article-title":"CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR. Recommendations and reports : Morbidity and mortality weekly report","volume":"62","author":"Schillie","year":"2013","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.omtm.2025.101646_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib51","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib52","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib53","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.omtm.2025.101646_bib55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350801300106","article-title":"Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication","volume":"13","author":"Lutgehetmann","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.omtm.2025.101646_bib57","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos (t) ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib60","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1128\/jvi.66.7.4073-4084.1992","article-title":"Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus","volume":"66","author":"Yuh","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.omtm.2025.101646_bib61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2022.04.005","article-title":"Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos (t) ide therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib63","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos (t) ide analog suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262516","article-title":"Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos (t) ide therapy","volume":"17","author":"Burdette","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101646_bib65","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4254\/wjh.v16.i3.331","article-title":"Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents","volume":"16","author":"Lam","year":"2024","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib66","series-title":"VIR-2218 and VIR-3434 with or without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results after 24 Weeks of Therapy (MARCH Study Part B). In 2","first-page":"E46","author":"Gane","year":"2024"},{"key":"10.1016\/j.omtm.2025.101646_bib67","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/jhep.2002.31867","article-title":"Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties","volume":"35","author":"Galun","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib68","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2019.07.003","article-title":"Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients","volume":"71","author":"Loglio","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","article-title":"Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN","volume":"64","author":"Fontaine","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.omtm.2025.101646_bib70","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.omtm.2025.101646_bib71","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jhep.2010.12.031","article-title":"Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges","volume":"54","author":"Michel","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtm.2025.101646_bib72","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101646_bib74","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(73)93321-7","article-title":"Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis","volume":"2","author":"Reed","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101646_bib75","article-title":"A Prospective, Open-Label, Dose-Escalation, Single-Center, Phase 1 Study for GC1102, a Recombinant Human Immunoglobulin for Chronic Hepatitis B Patients","author":"HW","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2025.101646_bib76","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/mabs.1.4.9122","article-title":"Human immunoglobulin allotypes: possible implications for immunogenicity","volume":"1","author":"Jefferis","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.omtm.2025.101646_bib77","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtm.2025.101646_bib78","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2025.101646_bib79","doi-asserted-by":"crossref","first-page":"220ra10","DOI":"10.1126\/scitranslmed.3007523","article-title":"Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy","volume":"6","author":"Childers","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101646_bib80","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101646_bib81","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.tiv.2006.06.003","article-title":"Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements","volume":"20","author":"Sohlenius-Sternbeck","year":"2006","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.omtm.2025.101646_bib82","doi-asserted-by":"crossref","first-page":"8308","DOI":"10.1128\/JVI.00833-10","article-title":"Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection","volume":"84","author":"Mason","year":"2010","journal-title":"J. Virol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125002414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125002414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:28:51Z","timestamp":1776198531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125002414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2329050125002414"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101646","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101646"}}